Abstracts tagged "Uric Acid, Urate"

Abstract Number: 1885 • ACR Convergence 2024
Effect of Physical Activity on Mortality in Rheumatoid Arthritis: A Dose-Response Analysis
Bo Chen¹ and Qibing Xie², ¹Chenbo, Chendu, Sichuan, China, ²Department of Rheumatology and Immunology, Chengdu, Sichuan, China
Background/Purpose: Patients with Rheumatoid arthritis (RA) tend to perform less physical activity compared to the recommended guidelines. The long-term effects of physical activity on mortality…
Abstract Number: 1898 • ACR Convergence 2024
Hyperuricemia Is Associated with Higher Levels of Fasting Plasma Glucose and Insulin Resistance in Non-diabetic Subjects
Janis Timsans¹, Jenni Kauppi¹, Anne Kerola², Vappu Rantalaiho³, Hannu Kautiainen⁴ and Markku Kauppi², ¹Päijät-Häme Central Hospital, Lahti, Finland, ²Päijät-Häme Central Hospital, University of Helsinki, Lahti, Finland, ³Tampere University Hospital, Tampere University and Kanta-Häme Central Hospital, Tampere, Finland, ⁴Folkhälsan Research Center, Helsinki, Finland
Background/Purpose: Disorders of glucose metabolism are well-known major contributors to morbidity and mortality. Elevated serum uric acid (SUA), a key precursor of gout attacks, is…
Abstract Number: 2005 • ACR Convergence 2024
Impact of Anti-drug Antibodies on the Efficacy of SEL-212 in Patients with Chronic Gout Refractory to Conventional Therapy
Puja Khanna¹, Vibeke Strand², Atul Singhal³, Herbert Baraf⁴, Rehan Azeem⁵, Wesley DeHaan⁶, Sheldon Leung⁵, Hugues Santin-Janin⁷, Aletta Falk⁸ and Alan Kivitz⁹, ¹University of Michigan, Ann Arbor, MI, ²Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ³Southwest Arthritis Research Group, Mesquite, TX, ⁴Center for Rheumatology and Bone Research, Wheaton, MD, ⁵Sobi Inc., Waltham, MA, ⁶Sobi, Inc, Waltham, MA, ⁷Sobi, BETTENDORF (68560), France, ⁸Sobi, Stockholm, Sweden, ⁹Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: SEL-212 is a once-monthly, investigational, two-component infusion therapy consisting of pegadricase (SEL-037, a pegylated uricase) and immune-tolerizing nanoparticles containing sirolimus (SEL-110), for the treatment…
Abstract Number: 2008 • ACR Convergence 2024
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Dose of ABP-671 in Participants with Chronic Kidney Disease (CKD)
ullrich schwertschlag¹, william dongfang Shi², rOBERT PERRY³, Kwabena Ayesu⁴, rOY WU⁵, jerry liu⁶, JinSying Lin⁷ and Adam Jin⁸, ¹Atombio Science, PALO ALTO, CA, ²Jiangsu Atom Bioscience,, Suzhou, Jiangsu, China (People's Republic), ³Panax Clin Res, Miami Lakes, FL, ⁴OMEGARLLC, ORLANDO, FL, ⁵Atom Bioscience, SAN FRANCISCO, CA, ⁶atombio, San Diego, CA, ⁷Biostatconsulting, Wuzhong, Suzhou, Jiangsu, China (People's Republic), ⁸atom biosciences, Wuzhong, Suzhou, Jiangsu, China (People's Republic)
Background/Purpose: In this open-label Phase 1 study, 22 participants were enrolled in 3 cohorts, 10 participants with normal kidney function (eGFR ≥90 ml/min/1.73m2 and no…
Abstract Number: 2012 • ACR Convergence 2024
Safety, Tolerability and Efficacy of Pegloticase Administered with a Shorter Infusion Duration in Subjects with Uncontrolled Gout Receiving Methotrexate: Primary Findings of the AGILE Open-label Trial
Orrin Troum¹, John Botson², Fang Fang³, Katie Obermeyer³, Supra Verma³ and Brian LaMoreaux⁴, ¹Providence Health Care/Doctor's of St John's (MDSJ) Santa Monica, CA, Santa Monica, CA, ²Orthopedic Physicians Alaska, Anchorage, AK, ³Amgen, Inc., Thousand Oaks, CA, ⁴Amgen, Inc., Deerfield, IL
Background/Purpose: Pegloticase, infused every 2 weeks over ≥2 hrs, lowers serum urate (SU) in patients with refractory gout. Decreasing infusion time is expected to improve…
Abstract Number: 2013 • ACR Convergence 2024
Elevated Serum Allantoin and Allantoin/uric Acid Ratio as Indicators of Oxidative Stress in Severe Gout and Cardiovascular Comorbidities
Lenka Hasikova¹, Petr Kozlik², Kveta Kalikova³, Petr Dusek⁴, Marketa Pavlikova¹, Blanka Stiburkova⁵ and Jakub Závada⁶, ¹Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Department of Analytical Chemistry, Faculty of Science, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Department of Physical and Macromolecular Chemistry, Faculty of Science, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Department of Neurology and Centre of Clinical Neuroscience and Department of Radiology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic, Prague, Czech Republic, ⁵Institute of Rheumatology, Prague, Czech Republic and Department of Paediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic, Prague, Czech Republic, ⁶Institute of Rheumatology and Charles University, Praha, Czech Republic
Background/Purpose: Uric acid (UA) can be non-enzymatically oxidized into allantoin and other products by reactive oxygen species under conditions of increased oxidative stress. Consequently, allantoin…
Abstract Number: 0265 • ACR Convergence 2024
Performance of Two Gout Remission Definitions in a Two-Year Randomized Controlled Trial of Nurse-led Care
Dansoa Tabi-Amponsah¹, Michael Doherty², Aliya Sarmanova³, Weiya Zhang², Sarah Stewart⁴, William Taylor⁵, Lisa Stamp⁶ and Nicola Dalbeth⁷, ¹The University of Auckland, Auckland, New Zealand, ²Academic Rheumatology, School of Medicine, University of Nottingham; Pain Centre Versus Arthritis, University of Nottingham, Nottingham, United Kingdom, ³Roche Diagnostics International, Clinical Development and Medical Affairs, Nottingham, England, United Kingdom, ⁴Auckland University of Technology, Auckland, New Zealand, ⁵The University of Otago, Wellington, Wellington, New Zealand, ⁶University of Otago, Christchurch, Christchurch, New Zealand, ⁷University of Auckland, Auckland, New Zealand
Background/Purpose: To compare the performance of the 2016 preliminary gout remission definition and a simplified gout remission definition in a clinical trial of nurse-led gout…
Abstract Number: 2014 • ACR Convergence 2024
Effect of a Whole Food Plant-Based Diet in Patients with Gout: A Pilot Randomized Controlled Trial
Anna Kretova¹, Carlijn Wagenaar¹, Wendy Walrabenstein², Daisy Vedder², Dirkjan van Schaardenburg² and Martijn Gerritsen¹, ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam UMC, Amsterdam, Netherlands
Background/Purpose: An unhealthy diet is an important modifiable risk factor for hyperuricemia and gout and is also associated with obesity and metabolic syndrome (MetS), known…
Abstract Number: 1103 • ACR Convergence 2023
Evaluation of Outcomes Following Discontinuation of Pegloticase Therapy
Emily Holladay¹, Amy S. Mudano², Fenglong Xie², Jingyi Zhang¹, Ted R Mikuls³, Brian LaMoreaux⁴, Lissa Padnick-Silver⁴ and Jeffrey Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Illumination Health, Hoover, AL, ³Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁴Horizon Therapeutics, Deerfield, IL
Background/Purpose: Little is known about the long-term effects of pegloticase therapy or what urate-lowering therapy (ULT) patients subsequently receive when they discontinue pegloticase. This analysis…
Abstract Number: 1104 • ACR Convergence 2023
Dotinurad, a Potent and Selective Uricosuric Agent, Exhibited Promising Pharmacokinetics and Pharmacodynamic Profiles to Significantly Reduce Serum Urate Levels Following Once Daily Dosing in Healthy U.S. Subjects in a Phase 1 Clinical Trial
Scott Baumgartner, Raymond Zheng, Mark Harnett and Jay Kranzler, Urica Therapeutics Inc., New York, NY
Background/Purpose: Dotinurad is a potent and selective URAT1 inhibitor that has been approved as a once-daily drug for the treatment of hyperuricemia with or without…
Abstract Number: 1105 • ACR Convergence 2023
Effects of Uric Acid Lowering Treatment on Vascular Stiffness in Gout Patients
Jinseok kim, Division of Rheumatology, Department of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, South Korea
Background/Purpose: Many studies have reported that gout and hyperuricemia are associated with an increase in all-cause mortality and cardiovascular mortality.Increased vascular stiffness is closely related…
Abstract Number: 1107 • ACR Convergence 2023
Predictors of Pegloticase Urate-lowering Response in the Presence and Absence of Methotrexate Co-therapy
James Mossell¹, Mai Duong², Katie Obermeyer², Lissa Padnick-Silver², Brian LaMoreaux² and Sanjay Chabra³, ¹Arthritis and Osteoporosis Center of South Georgia, Tifton, GA, ²Horizon Therapeutics, Deerfield, IL, ³Texas Arthritis Center, El Paso, TX
Background/Purpose: Pegloticase can lower serum urate (SU) in patients with uncontrolled gout who are refractory to/intolerant of oral urate-lowering therapies. However, antidrug antibodies (ADAs) can…
Abstract Number: 0038 • ACR Convergence 2023
Specific Binding of Uric Acid to NDFIP1 Associates with Hyperuricemia-induced Ferroptosis
Qiunan Zhu¹, Hiroshi Arakawa², Yoshiyuki Shirasaka² and Ikumi Tamai², ¹Kanazawa University, Kanazawa, Japan, ²Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan
Background/Purpose: Hyperuricemia (HU) is reported as a risk factor for gout and associates with diverse diseases, including ulcerative colitis (UC), while its mechanism remains unclear.…
Abstract Number: 1110 • ACR Convergence 2023
Pharmacokinetics and Pharmacodynamics of AR882 Following 12-Week Treatment in Patients with Gout
Roy Fleischmann¹, James Cheng-Chung Wei², Zancong Shen³, sarah Morris⁴, Elizabeth Polvent⁵, Andrea Clouser-Roche⁴, Vijay Hingorani⁶, Rongzi Yan⁷, Shunqi Yan⁸, Robert Keenan⁹ and Li-Tain Yeh¹⁰, ¹Division of Rheumatology, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ²Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan, ³Arthrosi Therapeutics, San Diego, CA, ⁴Arthrosi Therapeutics Inc, San Diego, CA, ⁵Arthrosi Therapeutics, Inc., Roseville, CA, ⁶Vanguard Healthsciences, Inc., San Diego, CA, ⁷Arthrosi Therapeutics, Inc, Irvine, CA, ⁸Arthrosi Therapeutics, Inc., Laguna Hills, CA, ⁹Arthrosi Therapeutics, Chapel Hill, NC, ¹⁰Arthrosi Therapeutics, Inc., Irvine, CA
Background/Purpose: In early phase studies AR882 exhibited good dose proportionality, long half-life and dose-dependent serum urate (sUA) lowering effect in a broad range of doses…
Abstract Number: 0048 • ACR Convergence 2023
Monosodium Urate Crystals Activate an Immune Tolerance Program That Restrains the Activation of Inflammatory Signaling in Macrophages During Gout Flares
Mohnish Alishala¹, Stephen Calderon¹, Anyan Chen¹, Monica Guma², Christopher glass¹ and Isidoro Cobo¹, ¹University of California San Diego, San Diego, CA, ²University of California San Diego, La Jolla, CA
Background/Purpose: Gout is the most frequent form of inflammatory arthritis, with episodes of self-resolving acute inflammation in the joint caused by the deposition of monosodium…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].